InvestorsHub Logo
Followers 20
Posts 918
Boards Moderated 0
Alias Born 04/17/2001

Re: Mocha Jet post# 204973

Tuesday, 06/14/2016 11:08:23 AM

Tuesday, June 14, 2016 11:08:23 AM

Post# of 410069
**** Elite Pharmaceuticals Conference Call Questions ****

Those participating in ELTP’s Conference Call Q&A session are limited to asking one question following ELTP management’s opening statements.
To make the most of this Q&A opportunity, suggest that we come up with a list to share of top questions to ask:

[copy/past list and add your question at the bottom]

1. ELI-200/SequestOx

A. FDA's Advisory Committee review of Pfizer's ALO 02/Troxyca ER determined that "Oxycodone can be selectively extracted from intact pellets
by a number of straightforward techniques and certain common solvents appear to be capable of removing naltrexone selectively from crushed pellets."
How do ELI-200/SequestOx's results compare if subjected to the same criteria?

B. Is a media/PR campaign planned if ELI-200/SequestOx receives FDA's approval and becomes the first and only IR ADT with label?

2. ELI-201.

A. Progress/status update.

B. There are multiple viable pathways to obtaining approval for ELI-201. Is it accurate to conclude that if anything other than ALO 02/Troxyca ER is
used as the direct comparator, then Phase 3 would be required?

3. Progress/status update on ELI-202.

4. Has Elite entertained the sale of its generic line of business since it would provide capital needed to push the balance of the portfolio through FDA submission?

5. How much does a fluid bed dryer cost? Does Elite have the room to add a 2nd 1000 Kilo or will they need a new
manufacturing site and/or partner?

6. When can we expect the shareholder's meeting?

7. Tell about the connections with the Chinese - and what future developments are you expecting.

"Life is tough, but it's tougher if you're stupid"... John Wayne (Sgt. Stryker - Sands of Iwo Jima)

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ELTP News